BioSpace

The race for access: How the FAIR Act could reclaim U.S. biotech leadership

In this episode of Denatured, you’ll hear from Max Bronstein, CEO of Aviva Strategies and Teresa Barnes, Chief Executive Warrior of PF Warriors. We dig into why U.S. patients are losing access to rare disease trials happening abroad and how the FAIR Act’s accelerated, harmonized reviews could help the U.S. keep pace while getting lifesaving studies to patients faster.

بقلم BioSpace

1 دقيقة قراءة
مشاركة
The race for access: How the FAIR Act could reclaim U.S. biotech leadership
The race for access: How the FAIR Act could reclaim U.S. biotech leadership

هل لديك أخبار لمشاركتها مع صناعة الفعاليات؟

أرسل بياناً صحفياً أو تلميحاً بقصة وتواصل مع آلاف المهنيين في مجال الفعاليات.

تواصل معنا→

المزيد في Health Tech

رؤى ذات صلة